Vizuro and NCKU Forge Partnership to Accelerate AI-Driven Biologics Innovation

Partnership with Professor Woei-Jer Chuang of NCKU to explore AI-powered discovery in protein drug design

Vizuro Apotek AI Drug Discovery Platform x Industry-Academia Collaboration with NCKU

Taipei | [October 27, 2025] — Vizuro LLC, a leading innovator in multimodal causal AI and generative AI for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) with Professor Woei-Jer Chuang, Ph.D., of the Department of Biochemistry and Molecular Biology, National Cheng Kung University (NCKU).

This partnership marks the beginning of discussions toward a formal industry–academic collaboration, combining Vizuro’s Apotek AI drug discovery platform with Professor Chuang’s deep expertise in structural biology, protein engineering, and protein drug design. Together, the two parties aim to accelerate innovation in AI-assisted biologics and antibody research. 

Under the MOU, Vizuro and NCKU will explore joint development projects utilizing Apotek’s AI-driven drug discovery capabilities, integrating both causal AI and generative AI approaches. The collaboration will focus on:

• Joint development of novel biologics grounded in causal biology, from early target discovery to translational research in autoimmune disease and oncology;

• Design of bispecific protein drug targeting multiple signaling pathways, including those regulating immune modulation;

• Integration of wet-lab and computational data to enhance predictive modeling accuracy;

• Exploration of AI applications in protein engineering and structural biology

Yu-Feng Wei, Co-founder and CEO of Vizuro, shared:

"By combining Apotek's causal AI and generative AI technologies with Professor Chuang’s expertise in structure-guided protein engineering, we’re shaping a new paradigm for biologics design — one that learns directly from molecular data and experimental evidence. We are redefining how antibodies and protein drugs can be designed—from omics data to discovery."

Woei-Jer Chuang, Professor of NCKU, added:

 “Our collaboration will integrate AI prediction with molecular insight, opening new possibilities to engineer proteins with enhanced specificity and therapeutic efficacy.”

About Apotek

Apotek harnesses groundbreaking causal AI and generative AI technologies to build an integrated platform that transforms multi-omics data into actionable insights — enabling novel target discovery, biosimulation, and generative drug design. By uncovering cause-and-effect relationships rather than spurious correlations, our approach enhances biological interpretability, improves model robustness, and accelerates decision-making across the drug discovery pipeline. Learn more about Apotek here↗

About Professor Woei-Jer Chuang

Professor Chuang earned his Ph.D. in Chemistry from Florida State University and serves as a leading faculty member at NCKU’s Department of Biochemistry and Molecular Biology. His research spans protein drug design on integrin-specific disintegrins and interleukin 2, protein biotechnology, and structural biology, contributing to understanding integrin recognition, protein–ligand interactions, and thrombosis mechanisms. With over 100 peer-reviewed publications, 57 research projects, 45 patents, 62 patents pending, and the development of a biologic for diabetic retinopathy in a phase II trial, Professor Chuang’s work has advanced fields ranging from bispecific cancer biologics to SARS-CoV-2 antibody mechanisms.

Media Contact

Esther Chen,

Director of Business Operations of Commercialization,

Vizuro LLC